@article{873a51cd2d8d4b669e134e9f58a57caf,
title = "AUTACs: Cargo-Specific Degraders Using Selective Autophagy",
abstract = "Protein silencing represents an essential tool in biomedical research. Targeted protein degradation (TPD) strategies exemplified by PROTACs are rapidly emerging as modalities in drug discovery. However, the scope of current TPD techniques is limited because many intracellular materials are not substrates of proteasomal clearance. Here, we described a novel targeted-clearance strategy (autophagy-targeting chimera [AUTAC]) that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity. As expected from the substrate scope of autophagy, AUTAC degraded fragmented mitochondria as well as proteins. Mitochondria-targeted AUTAC accelerated both the removal of dysfunctional fragmented mitochondria and the biogenesis of functionally normal mitochondria in patient-derived fibroblast cells. Cytoprotective effects against acute mitochondrial injuries were also seen. Canonical autophagy is viewed as a nonselective bulk decomposition system, and none of the available autophagy-inducing agents exhibit useful cargo selectivity. With its target specificity, AUTAC provides a new modality for research on autophagy-based drugs.",
keywords = "AUTAC, Down syndrome, K63-linked polyubiquitin, PROTACs, S-guanylation, autophagy, cargo-specific degrader, drug discovery, mitophagy, targeted protein degradation",
author = "Daiki Takahashi and Jun Moriyama and Tomoe Nakamura and Erika Miki and Eriko Takahashi and Ayami Sato and Takaaki Akaike and Kaori Itto-Nakama and Hirokazu Arimoto",
note = "Funding Information: We are grateful to Dr. Noboru Mizushima (University of Tokyo) for providing us with Atg5 −/− MEF cells, Dr. Toru Yanagawa (University of Tsukuba) for providing us with p62 −/− MEF cells, Dr. Noriyuki Matsuda (Tokyo Metropolitan Institute of Medical Science) for providing us with PINK1 −/− HeLa cells, and Drs. Makoto Sasaki and Atsushi Higashitani (Tohoku University) for their technical assistance. This research was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan Society for the Promotion of Science (MEXT, JSPS), KAKENHI (grant numbers JP15H0117 , JP16H03289 , JP17K19190 , JP18H04604 , JP18H04377 , JP19H02844 , JP25282236 , and JP26102706 ); Japan Agency for Medical Research and Development (AMED) (grant numbers JP18ae0101048 , JP18am0101100 , and JP19ae0101048 ); the Naito Foundation ; and the Uehara Memorial Foundation . Funding Information: We are grateful to Dr. Noboru Mizushima (University of Tokyo) for providing us with Atg5−/− MEF cells, Dr. Toru Yanagawa (University of Tsukuba) for providing us with p62−/− MEF cells, Dr. Noriyuki Matsuda (Tokyo Metropolitan Institute of Medical Science) for providing us with PINK1−/− HeLa cells, and Drs. Makoto Sasaki and Atsushi Higashitani (Tohoku University) for their technical assistance. This research was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan Society for the Promotion of Science (MEXT, JSPS), KAKENHI (grant numbers JP15H0117, JP16H03289, JP17K19190, JP18H04604, JP18H04377, JP19H02844, JP25282236, and JP26102706); Japan Agency for Medical Research and Development (AMED) (grant numbers JP18ae0101048, JP18am0101100, and JP19ae0101048); the Naito Foundation; and the Uehara Memorial Foundation. D.T. and H.A. designed the projects. D.T. J.M. T.N. E.M. E.T. A.S. and K.I.-N. conducted the synthetic and cell-based experiments. T.A. prepared the anti-S-guanylation antibody and analyzed the data. D.T. and H.A. analyzed the data and wrote the paper. Tohoku University has filed patent applications including results from this study. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2019",
month = dec,
day = "5",
doi = "10.1016/j.molcel.2019.09.009",
language = "English",
volume = "76",
pages = "797--810.e10",
journal = "Molecular Cell",
issn = "1097-2765",
publisher = "Cell Press",
number = "5",
}